Back

The effect of an incentive billing code on heart failure management in primary care: a population-based study

11 May 2024 (08:00 - 20:00)
Organised by: Logo
Congress Presentation Part of: Chronic heart failure - treatment 9 Pharmacotherapy HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Shijie Zhou

University of Toronto, Toronto (Canada)

7 More presentations in this session

Presentation thumbnail
Real world data using sacubitril/valsartan in CKD stage 4 and 5 is associated with improved ejection fraction and may have renoprotective effects.
Doctor M. Sweeney (London, GB)
Abstract Slides Video
Presentation thumbnail
Real-life management of heart failure: evaluation of medication optimisation in different phenotypes.
Miss H. Hauksdottir (Reykjavik, IS)
Abstract Slides Video
Presentation thumbnail
A novel dual-action insulin secreting and natriuretic peptide, CRRL 101, a potential therapy for diabetic cardiomyopathy
Doctor I. Isaia (Rochester, US)
Abstract Slides Video
Presentation thumbnail
Evaluation of the effects of the Sodium-glucose cotransporter 2 inhibitors and sacubitril/valsartan combined therapy in patients with HFrEF: echocardiographic study.
Doctor I. Fumarulo (Rome, IT)
Abstract Slides Video
Presentation thumbnail
Persistence of autoantibodies directed against the beta-1-adrenoceptor in patients with heart failure after treatment with BC 007 (Rovunaptabin). Results of a phase IIa study.
Associate Professor M. Zdravkovic (Belgrade, RS)
Abstract Slides

Access the full session

Session thumbnail
Chronic heart failure - treatment 9

The Event

Event poster

Heart Failure 2024

11 May - 14 May 2024
You may be interested in
thumbnail
Congress Presentation
PRACTICE-HF : an implementation study of an updated acute heart failure protocol.
thumbnail
Congress Presentation
Empowering delivery of improved heart failure care in primary care - an integrated heart failure project
thumbnail
Congress Presentation
Therapeutic optimization score for patients with heart failure and reduced ejection fraction in a low-middle income country: Design and score implementation for the OPTIMAL-HF trial

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources